Cite
Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.
MLA
Balakirouchenane, David, et al. “Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.” Thyroid, vol. 33, no. 11, Nov. 2023, pp. 1327–38. EBSCOhost, https://doi.org/10.1089/thy.2023.0228.
APA
Balakirouchenane, D., Seban, R., Groussin, L., Puszkiel, A., Cottereau, A. S., Clerc, J., Vidal, M., Goldwasser, F., Arrondeau, J., Blanchet, B., & Huillard, O. (2023). Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer. Thyroid, 33(11), 1327–1338. https://doi.org/10.1089/thy.2023.0228
Chicago
Balakirouchenane, David, Romain Seban, Lionel Groussin, Alicja Puszkiel, Anne Ségolène Cottereau, Jerome Clerc, Michel Vidal, et al. 2023. “Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.” Thyroid 33 (11): 1327–38. doi:10.1089/thy.2023.0228.